Thyroid Function and Longevity: What TSH and T4 Tell You, and When Treatment Helps
The thyroid gland produces the hormones that set the metabolic rate of every cell in the body. Thyroid dysfunction — both overt and subclinical — is among the most prevalent endocrine conditions in adults, affecting an estimated 20 million Americans. Routine screening of people without symptoms is not recommended by the US Preventive Services Task Force, which found the evidence insufficient, but testing is worthwhile when symptoms suggest a problem, given the thyroid’s fundamental role in metabolism, cardiovascular health, cognitive function, and body composition.
- The thyroid gland produces thyroxine (T4, the storage form) and triiodothyronine (T3, the active form). T4 is converted to T3 in peripheral tissues by deiodinase enzymes. T3 binds nuclear thyroid hormone receptors and directly regulates gene expression for metabolic rate, cardiac function, thermogenesis, lipid metabolism, brain development, and virtually every organ system.
- Subclinical hypothyroidism — elevated TSH with normal free T4, affecting 4-8 percent of adults and up to 20 percent of women over 60 — is associated with elevated LDL-C, elevated cardiovascular risk, reduced exercise tolerance, cognitive slowing, fatigue, and impaired glucose metabolism. Treatment is clearly recommended when TSH stays above 10 mIU/L; below that, decisions are individualized, and a large trial in adults 65 and older found no benefit from treatment.
- TSH is the recommended first test because it is the most sensitive marker of thyroid function; free T4 is added when TSH is abnormal, and TPO antibodies help diagnose autoimmune thyroid disease. Routine reverse T3 testing is not recommended by guidelines.
- Hashimoto's thyroiditis — autoimmune thyroid disease — is the most common cause of hypothyroidism in developed countries and affects an estimated 5 percent of the population. It can be asymptomatic for years before TSH rises, during which time thyroid antibodies (TPO Ab) are elevated and thyroid tissue is being progressively destroyed. Early identification via TPO antibody testing allows earlier intervention and potentially slows disease progression.
- There is no evidence-based “optimal” TSH for longevity. TSH naturally rises with age, and a study of centenarians found that exceptional longevity was associated with higher, not lower, TSH.
The thyroid gland's hormones — thyroxine (T4) and triiodothyronine (T3) — are the body's primary metabolic regulators. T3 binds to nuclear thyroid hormone receptors distributed in virtually every cell type and directly regulates the expression of genes controlling oxygen consumption, protein synthesis, carbohydrate and lipid metabolism, cardiac contractility, thermogenesis, and neuronal function. The metabolic rate you have, the body temperature you maintain, the rate at which you burn fat, the efficiency of your heart, and the clarity of your thinking are all substantially determined by your thyroid hormone levels.1
The T4/T3 Conversion Problem
The thyroid gland secretes approximately 80 percent of its output as T4 and 20 percent as T3. T4 is relatively inert (approximately 10 times less potent than T3) and serves primarily as a circulating reservoir that peripheral tissues convert to active T3 via type 1 and type 2 deiodinase enzymes. This local conversion lets each tissue fine-tune its own thyroid hormone activity.2
Factors that impair T4-to-T3 conversion include: selenium deficiency (deiodinase enzymes are selenoproteins), zinc deficiency, chronic illness or inflammation, very low-calorie dieting, high cortisol (stress), certain medications (amiodarone, beta-blockers, glucocorticoids, lithium), and aging itself (peripheral deiodinase activity declines with age). In serious illness this can produce low T3 with high reverse T3 (an inactive form), a pattern called non-thyroidal illness that usually does not need thyroid treatment.
Subclinical Hypothyroidism: The Treatment Controversy
Subclinical hypothyroidism (SCH) — defined as elevated TSH (above 4.0-4.5 mIU/L depending on the laboratory) with normal free T4 — affects 4 to 8 percent of adults and up to 20 percent of women over 60. The clinical significance and treatment threshold for SCH is one of the most actively debated topics in endocrinology. The case for treatment: SCH is associated with elevated LDL-C (thyroid hormone regulates LDL receptor expression), elevated cardiovascular risk (particularly when TSH is above 10 mIU/L), cognitive symptoms, fatigue, weight gain, and impaired exercise tolerance. A meta-analysis of 11 cohort studies found that SCH with TSH above 10 mIU/L was associated with significantly elevated cardiovascular mortality.3
Current guidelines recommend treatment for SCH with TSH consistently above 10 mIU/L5 and individualized decision-making for TSH between 4.5 and 10 mIU/L in adults under 65. For older adults, the TRUST trial randomized 737 people aged 65 and over with subclinical hypothyroidism to levothyroxine or placebo and found no apparent benefit.6 TSH also rises naturally with age: in a study of centenarians, exceptional longevity was associated with higher TSH, so mildly raised TSH in very old age may be normal.7
Hashimoto's Thyroiditis: Early Detection Matters
Hashimoto's thyroiditis is an autoimmune condition in which TPO (thyroid peroxidase) and thyroglobulin antibodies progressively damage thyroid tissue. It can remain subclinical for years to decades — with elevated TPO antibodies (typically above 35 IU/mL) but normal TSH — during which time thyroid follicular cells are being destroyed by lymphocytic infiltration. By the time TSH rises to the SCH or overt hypothyroidism range, significant thyroid tissue has already been lost. Early identification via TPO antibody testing in adults with symptoms (fatigue, cold intolerance, weight gain, hair loss, brain fog) — even with normal TSH — allows closer monitoring, so treatment can start promptly if thyroid function declines.4
Selenium supplementation (200 mcg/day of selenomethionine) reduced TPO antibody levels at 3 months and improved reported well-being in a meta-analysis of small trials in people already taking thyroid medication, but it has not been shown to slow disease progression. It is not risk-free: in a large prevention trial, 200 mcg of selenium a day was linked to a higher risk of type 2 diabetes (hazard ratio 1.55).8 Discuss it with your doctor rather than taking it routinely. The mechanism: selenium is required for selenoprotein synthesis including the glutathione peroxidases and deiodinases that protect thyroid cells from the oxidative damage generated by thyroid hormone synthesis.
Put this research into practice: Biomarker Reference Tool · What Should I Test Next?
References
- 1Brent GA. "Mechanisms of thyroid hormone action." J Clin Invest. 2012;122(9):3035-43. PubMed · DOI
- 2Bianco AC, Kim BW. "Deiodinases: implications of the local control of thyroid hormone action." J Clin Invest. 2006;116(10):2571-9. PubMed · DOI
- 3Rodondi N, et al. "Subclinical hypothyroidism and the risk of coronary heart disease and mortality." JAMA. 2010;304(12):1365-74. PubMed · DOI
- 4Toulis KA, et al. "Selenium supplementation in the treatment of Hashimoto's thyroiditis: a systematic review and a meta-analysis." Thyroid. 2010;20(10):1163-73. PubMed · DOI
- 5Garber JR, et al. "Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association." Thyroid. 2012;22(12):1200-35. PubMed · DOI
- 6Stott DJ, et al. "Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism." N Engl J Med. 2017;376(26):2534-2544. PubMed · DOI
- 7Atzmon G, et al. "Extreme longevity is associated with increased serum thyrotropin." J Clin Endocrinol Metab. 2009;94(4):1251-4. PubMed · DOI
- 8Stranges S, et al. "Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial." Ann Intern Med. 2007;147(4):217-23. PubMed · DOI
